BNC KOREA, Inc. (KOSDAQ:256840)

South Korea · Delayed Price · Currency is KRW

2,210.00

-40.00 (-1.78%)

Nov 13, 2026, 3:30 PM KST

Market Cap	151.15B -57.9%
Revenue (ttm)	91.19B -8.2%
Net Income	-4.72B
EPS	-68.97
Shares Out	68.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	70.00 (3.17%)
Ex-Dividend Date	Dec 29, 2026

Volume	225,484
Open	2,250.00
Previous Close	2,250.00
Day's Range	2,210.00 - 2,325.00
52-Week Range	2,050.00 - 6,180.00
Beta	1.16
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About BNC KOREA

BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers and ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2007

Employees 271

Stock Exchange KOSDAQ

Ticker Symbol 256840

Full Company Profile

Financial Performance

In 2025, BNC KOREA's revenue was 95.90 billion, an increase of 7.47% compared to the previous year's 89.23 billion. Earnings were 2.84 billion, a decrease of -78.68%.

Financial Statements